상위피인용논문
- 조회782
한림대학교 춘천성심병원, Galgotias University
Chiranjib Chakraborty1,2,4,*, Ashish Ranjan Sharma2,4, Garima Sharma2, C. George Priya Doss3, Sang-Soo Lee2,*
1 Department of Bioinformatics and Biochemistry, Galgotias University, Greater Noida 201306, Uttar Pradesh, India
2 Institute for Skeletal Aging & Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon 24252, Republic of Korea
3 Department of Integrative Biology, VIT University, Vellore 632014, Tamil Nadu, India
4 These authors contributed equally to this work.
*Corresponding authors
Abstract
In the past few years, therapeutic microRNA (miRNA) and small interfering RNA (siRNA) are some of the most important biopharmaceuticals that are in commercial space as future medicines. This review summarizes the patents of miRNA- and siRNA-based new drugs, and also provides a snapshot about significant biopharmaceutical companies that are investing for the therapeutic development of miRNA and siRNA molecules. An insightful view about individual siRNA and miRNA drugs has been depicted with their present status, which is gaining attention in the therapeutic landscape. The efforts of the biopharmaceuticals are discussed with the status of their preclinical and/or clinical trials. Here, some of the setbacks have been highlighted during the biopharmaceutical development of miRNA and siRNA as individual therapeutics. Finally, a snapshot is illustrated about pharmacokinetics, pharmacodynamics with absorption, distribution, metabolism, and excretion (ADME), which is the fundamental development process of these therapeutics, as well as the delivery system for miRNA- and siRNA-based drugs.
Keywords : miRNA; siRNA; drug development
논문정보
- Review Paper
- 2017년 09월 (BRIC 등록일 2019-05-09)
- 국내(교신)+국외 연구진
- 60회 이상 인용된 논문
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
